Progress in the diagnosis and treatment of Rosai-Dorfman disease

doi:10.16352/j.issn.1001-6325.2022.11.1785

Abstract

Abstract: Rosai-Dorfman disease (RDD) is a rare non-Langerhans cell histiocytosis. Its etiology and pathogenesis are yet incompletely elucidated. The clinical manifestations of RDD are highly heterogeneous. It is easy to be misdiagnosed or missed diagnosis. There is no standard treatment at present. Therefore, the progression in pathogenesis, diagnosis and treatment are reviewed. The treatment of RDD is best tailored to the individual clinical circumstances. Observation is suitable for patients with uncomplicated lymphadenopathy or asymptomatic cutaneous RDD. For RDD patients with extra nodal unifocal disease or organ compression, surgery is recommended. Systemic therapy can be considered for patients with systemic, recurrent or refractory RDD.

Key words: Rosai-Dorfman disease, clinical manifestations, treatment

CLC Number:

R559

LIU Ting, CAO Xin-xin. Progress in the diagnosis and treatment of Rosai-Dorfman disease[J]. Basic & Clinical Medicine, 2022, 42(11): 1785-1790.

References 26

[1]	Mahzoni P, Zavareh MHT, Bagheri M, et al. Intracranial Rosai-Dorfman disease[J]. J Res Med Sci, 2012, 17: 304-307.
[2]	Garces S, Medeiros LJ, Patel KP, et al. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease[J]. Mod Pathol, 2017, 30: 1367-1377.
[3]	Levine PH, Jahan N, Murari P, et al. Detection of human herpesvirus 6 in tissues involved by sinus histiocytosis with massive lymphadenopathy(Rosai-Dorfman disease)[J]. J Infect Dis, 1992, 166: 291-295.
[4]	Diamond EL, Durham BH, Haroche J, et al. Diverse and targetable kinase alterations drive histiocytic neoplasms[J]. Cancer Discov, 2016, 6: 154-165.
[5]	Durham BH, Lopez Rodrigo E, Picarsic J, et al. Activat-ing mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms[J]. Nat Med, 2019, 25: 1839-1842.
[6]	Fatobene G, Haroche J, Hélias-Rodzwicz Z, et al. BRAF V600E mutation detected in a case of Rosai-Dorfman disease[J].Haematologica,2018, 103: e377-e379.
[7]	Chen J, Zhao AL, Duan MH, et al. Diverse kinase alterations and myeloid-associated mutations in adult histiocytosis[J].Leukemia,2021.doi: 10.1038/s41375-021-01439-3.
[8]	Abla O, Jacobsen E, Picarsic J, et al. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease[J]. Blood, 2018, 131: 2877-2890.
[9]	Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy(Rosai-Dorfman disease): review of the entity[J]. Semin Diagn Pathol, 1990, 7: 19-73.
[10]	Sandoval-Sus JD, Sandoval-Leon AC, Chapman JR, et al. Rosai-Dorfman disease of the central nervous system: report of 6 cases and review of the literature[J]. Medicine(Baltimore), 2014, 93: 165-175.
[11]	刘旭, 胡余昌, 唐立华. Rosai-Dorfman病研究进展[J]. 中华病理学杂志,2017, 46: 443-446.
[12]	Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages[J]. Blood, 2016, 127: 2672-2681.
[13]	Goyal G, Ravindran A, Young JR, et al. Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease[J]. Haematologica, 2020, 105: 348-357.
[14]	Pulsoni A, Anghel G, Falcucci P, et al. Treatment of sinus histiocytosis with massive lymphadenopathy(Rosai-Dorfman disease): report of a case and literature review[J]. Am J Hematol, 2002, 69: 67-71.
[15]	Lima FB, Barcelos PS, Constâncio APN, et al. Rosai-Dorfman disease with spontaneous resolution: case report of a child[J]. Rev Bras Hematol Hemoter, 2011, 33: 312-314.
[16]	Al-Khateeb THH. Cutaneous Rosai-Dorfman disease of the face: a comprehensive literature review and case report[J]. J Oral Maxillofac Surg, 2016, 74: 528-540.
[17]	Forest F, N'Guyen AT, Fesselet J, et al. Meningeal Rosai-Dorfman disease mimicking meningioma[J]. Ann Hematol, 2014, 93: 937-940.
[18]	Cooper SL, Arceci RJ, Gamper CJ, et al. Successful treatment of recurrent autoimmune cytopenias in the context of sinus histiocytosis with massive lymphadeno-pathy using sirolimus[J]. Pediatr Blood Cancer, 2016, 63: 358-360.
[19]	Wang W, Sun J, Zhang W, et al. Successful treatment of intracranial Rosai-Dorfman disease with cytarabine and dexamethasone: case report and review of literature[J]. Ann Hematol, 2020, 99: 1157-1159.
[20]	Simko SJ, Tran HD, Jones J, et al. Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease[J]. Pediatr Blood Cancer, 2014, 61: 479-487.
[21]	Chen E, Pavlidakey P, Sami N. Rosai-Dorfman disease successfully treated with thalidomide[J]. JAAD Case Rep, 2016, 2: 369-372.
[22]	Rubinstein M, Assal A, Scherba M, et al. Lenalidomide in the treatment of Rosai Dorfman disease—a first in use report[J]. Am J Hematology, 2016, 91: E1.doi:10.1002/ajh.24225.
[23]	Jacobsen E, Shanmugam V, Jagannathan J. Rosai-Dorf-man disease with activating KRAS mutation-response to cobimetinib[J]. N Eng J Medicine, 2017, 377: 2398-2399.
[24]	Moyon Q, Boussouar S, Maksud P, et al. Lung involvement in Destombes-Rosai-Dorfman disease: clinical and radiological features and response to the MEK inhibitor cobimetinib[J]. Chest, 2020, 157: 323-333.
[25]	Giuffrè C, Giuffrè G. Choroidal involvement in Rosai-Dorfman disease successfully treated with cobimetinib[J]. Indian J Ophthalmol, 2020, 68: 2051-2053.
[26]	Mastropolo R, Close A, Allen S W, et al.BRAF-V600E-mutated Rosai-Dorfman-Destombes disease and Langer-hans cell histiocytosis with response to BRAF inhibitor[J]. Blood Adv, 2019, 3: 1848-1853.